Bionano Genomics Inc Asset Resilience Ratio
Bionano Genomics Inc asset resilience ratio. Bionano Genomics Inc (BNGO) has an Asset Resilience Ratio of 13.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bionano Genomics Inc (BNGO) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bionano Genomics Inc (2020–2025)
Asset resilience ratio of Bionano Genomics Inc from 2020 to 2025. This chart shows how Bionano Genomics Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Bionano Genomics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bionano Genomics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Bionano Genomics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.19 Million | 13.0% |
| Total Liquid Assets | $6.19 Million | 13.00% |
Asset Resilience Insights
- Moderate Liquidity: Bionano Genomics Inc has 13.00% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Bionano Genomics Inc Industry Peers by Asset Resilience Ratio
Compare Bionano Genomics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Caina Technology Co. Ltd.
SHE:301122 |
Medical Instruments & Supplies | 19.55% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
Ocumetics Technology Corp
V:OTC |
Medical Instruments & Supplies | 0.00% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 22.60% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
Bionano Genomics Inc Asset Resilience Ratio by Year (2020–2025)
Bionano Genomics Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Bionano Genomics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.95% | $10.27 Million | $73.58 Million | +13.56pp |
| 2024-12-31 | 0.39% | $302.00K | $76.67 Million | -22.38pp |
| 2023-12-31 | 22.77% | $48.82 Million | $214.40 Million | -12.38pp |
| 2022-12-31 | 35.15% | $108.09 Million | $307.50 Million | -24.79pp |
| 2021-12-31 | 59.94% | $226.04 Million | $377.10 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $60.45 Million | -- |
About Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simpl… Read more